JNJ-54767414

DRUG3 trials

Sponsors

Janssen - Cilag International, Janssen Cilag International

Conditions

AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)Multiple MyelomaPrecancerous form of blood cancer in the bone marrow

Phase 2

A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma CARTITUDE-2

Active, not recruitingCTIS2023-506587-13-00

Janssen - Cilag InternationalMultiple Myeloma

Start: 2020-01-30Target: 56Updated: 2025-09-02

Phase 3

A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma

Active, not recruitingCTIS2023-507143-11-00

Janssen - Cilag InternationalPrecancerous form of blood cancer in the bone marrow

Start: 2017-11-08Target: 144Updated: 2025-12-10

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

CompletedCTIS2024-511967-26-00

Janssen Cilag InternationalAL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)

Start: 2016-11-21End: 2024-11-13Target: 108Updated: 2024-07-22